Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Who Took Part

The abstract describes 249 children taking part.

By PubMed's age tags, the people studied were infants, young children and children, both men and women.

This international, multicentre, randomised, double-blind, placebo-controlled trial enrolled 249 children with RRTIs from Slovakia, Czech Republic, and Serbia.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Neither the children nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.

Primary endpoint was total respiratory tract infections (RTIs).

Secondary endpoints included RTI subtypes, RTI duration, missed school days, and safety evaluations.

What Was Measured

The subject headings attached to it are Respiratory Tract Infections, Dietary Supplements, Vitamin D and Zinc.

Author keywords: Biologically active polysaccharides, Children, Oyster mushroom, Pleuran and β-Glucan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 249 children.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Advances in therapy), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.